In:
Clinical Transplantation, Wiley, Vol. 32, No. 2 ( 2018-02)
Abstract:
In 2012, an Italian Named Patient Program began for hepatitis C virus ( HCV )‐infected liver transplant ( LT ) recipients with advanced fibrosis, before approval of direct antiviral agents ( DAA ), to benefit severely ill patients. The aim of this “real‐life” study was to assess treatment efficacy and safety with an extended course of daclatasvir ( DCV ) plus sofosbuvir ( SOF ) with or without ribavirin ( RBV ). Methods All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV + SOF ± RBV for 24 weeks; sustained virological response was assessed at 12 weeks post‐treatment ( SVR 12). Results Eighty‐seven patients were enrolled (75.9% males, mean age 58.4 ± 7.2 years, 83.9% genotype 1, 81.6% cirrhosis); 52 (59.8%) received RBV . Overall, 79 obtained SVR 12 (90.8%): 100% in F3 and 88.7% in cirrhotics (91.5% in Child‐Pugh A, 83.3% in Child‐Pugh B and C). According to the treatment group, SVR was 80% in DCV + SOF group and 98.1% in SOF + DCV + RBV . Two virological relapses occurred during follow‐up in cirrhotic patients who received DCV + SOF . Four cirrhotic patients in DCV + SOF group and 1 in DCV + SOF + RBV group died on treatment. Conclusion An extended course of SOF plus DCV for 24 weeks, with or without RBV , is effective and well tolerated for the treatment of post‐ LT HCV recurrence with severe fibrosis.
Type of Medium:
Online Resource
ISSN:
0902-0063
,
1399-0012
DOI:
10.1111/ctr.2018.32.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2739458-X
detail.hit.zdb_id:
2004801-4
Permalink